IL6 and irritable bowel syndrome: In addition, it is also suggested in experiments that TXYF can alleviate the behavioral hyperalgesia, which also shows antidiarrheal activity related to inhibiting the activated intestinal mucosal mast cells, downregulating the expression of protease activated receptor-2 (PAR-2) and oncogene fos (c-Fos), and lowering the levels of TNF-α and IL-6 in rats with postinfective IBS [45, 46].